Abstract:Background: The ability of a tumor to become dormant in response to suboptimal conditions has recently been recognized as a key step in tumor progression. Tumor dormancy has been found to be implicated in several tumor types as the culprit of therapy resistance and metastasis development, the deadliest features of a cancer. Several lines of evidence indicate that the development of these traits may rely on the de-differentiation of committed tumor cells that regain stem-like properties during a dormant state. Presently, dormancy is classified into cell- and population-level, according to the preponderance of cellular mechanisms that keep tumor cells quiescent or to a balance between overall cell division and death, respectively. Cellular dormancy is characterized by autophagy, stress-tolerance signaling, microenvironmental cues and, of prime relevance, epigenetic modifications. It has been found that the epigenome alters during cellular quiescence, thus representing the driving force for short-term cancer progression. Population-level dormancy is characterized by processes that counteract proliferation, such as inappropriate blood supply and intense immune responses. The latter two mechanisms are not mutually exclusive and may affect tumor masses both simultaneously and subsequently. Conclusions: Overall, tumor dormancy may represent an additional step in the acquisition of cancer characteristics, and its comprehension may clarify both theoretical and practical aspects of cancer development. Clinically, only a deep understanding of dormancy may explain the course of tumor development in different patients, thus representing a process that may be targeted to prevent and/or treat advanced-stage cancers. That is especially the case for breast cancer, against which the mTOR inhibitor everolimus displays potent antitumor activity in patients with metastatic disease by impeding autophagy and tumor dormancy onset. Here we will also discuss other targeted therapies directed towards tumor dormancy onset, e.g. specific inhibitors of SFK and MEK, or aimed at keeping tumor cells dormant, e.g. prosaposin derivatives, that may shortly enter clinical assessment in breast, and possibly other cancer types.

Sweet dreams: glycosylation controls tumor cell dormancy

Glycosylation in the Tumor Immune Response: the Bitter Side of Sweetness

Abstract SY34-01: Plasticity, dormancy, and glycosylation of circulating tumor cell clusters in response to therapy

Mechanisms of disseminated cancer cell dormancy: an awakening field

From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (<i>Artemia</i>)

TGF-beta Family Signaling Pathways in Cellular Dormancy

Developing a dormancy-associated ECM signature in TNBC that is linked to immunosuppressive tumor microenvironment and selective sensitivity to MAPK inhibitors

Dormancy-inducing 3D-engineered matrix uncovers mechanosensitive and drug protective FHL2-p21 signaling axis

Dormancy and awakening of cancer cells: the extracellular vesicle-mediated cross-talk between Dr. Jekill and Mr. Hyde

Abstract 2014: Tumor glycosylation impacts the efficacy of HER2 targeting therapies

Targeting cancer cell dormancy

Advances in the molecular regulation mechanism of tumor dormancy and its therapeutic strategy

Deciphering Dormant Cells of Lung Adenocarcinoma: Prognostic Insights from O-glycosylation-Related Tumor Dormancy Genes Using Machine Learning

Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications

Tumor Dormancy Within the Lymphovascular Embolus Is Regulated by Multiple Metabolism-signaling Pathways

Implication of the Extracellular Matrix in Metastatic Tumor Cell Dormancy

The current paradigm and challenges ahead for the dormancy of disseminated tumor cells

Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces

Outlook and opportunities for engineered environments of breast cancer dormancy

Unveiling the role of cellular dormancy in cancer progression and recurrence

Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy